Future of ophthalmic anti-infective therapy and the role of moxifloxacin ophthalmic solution 0.5% (VIGAMOX®)

Survey of Ophthalmology

Volumn 50, Issue 6 SUPPL. 1, 2005, Pages

  Schlech, Barry A ^a   Blondeau, Joseph ^b  

^a ALCON RESEARCH LTD   (United States)

^b ROYAL UNIVERSITY HOSPITAL   (Canada)

Author keywords

Benzalkonium chloride; Ciprofloxacin; Fluoroquinolones; Gatifloxacin; Levofloxacin; Moxifloxacin; Ofloxacin; Ophthalmic therapy; VIGAMOX

Indexed keywords

MOXIFLOXACIN;

ANTIBIOTIC RESISTANCE; CLINICAL TRIAL; CONJUNCTIVITIS; DRUG EFFICACY; DRUG POTENCY; EYE INFECTION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW;

EID: 27844600344     PISSN: 00396257     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.survophthal.2005.05.005     Document Type: Article

References (28)

1. R. Abshire, P. Cockrum, J. Crider, and B. Schlech Topical antibacterial therapy for mycobacterial keratitis: potential for surgical prophylaxis and treatment Clin Ther 26 2004 191 197
2. G. Alexandrakis, E.C. Alfonso, and D. Miller Shifting trends in bacterial keratitis in South Florida and emerging resistance to fluoroquinolones Ophthalmology 107 2000 1497 1502
3. E. Aliprandis, J. Ciralsky, and H. Lai Comparative efficacy of topical moxifloxacin versus ciprofloxacin and vancomycin in the treatment of P. aeruginosa and ciprofloxacin-resistant MRSA keratitis in rabbits Cornea 24 2005 201 205
4. J.M. Blondeau Fluoroquinolones: mechanism of action, classification, and development of resistance Surv Ophthalmol 49 Suppl 2 2004 S73 S78
5. J.M. Blondeau A review of the comparative in-vitro activities of 12 antimicrobial agents, with a focus on five new "respiratory quinolone" J Antimicrob Chemother 43 Suppl B 1999 1 11
6. J.M. Blondeau, G. Hansen, K. Metzler, and P. Hedlin The role of PK/PD parameters to avoid selection and increase of resistance: mutant prevention concentration J Chemother 16 Suppl 3 2004 1 19
7. D.W. Bratzler, and P.M. Houck Surgical Infection Prevention Guidelines Writers Workgroup: Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project Clin Infect Dis 38 2004 1706 1715
8. T.M. Chou, F. Gigliotti, and S.J. Lichtenstein Bacterial conjunctivitis: setting a course for containment and cure Contemp Pediatr 49 2004 1 8
9. J. Dajcs, J. Moreau, and B.A. Thibodeaux Effectiveness of ciprofloxacin and ofloxacin in a prophylaxis model of Staphylococcus keratitis Cornea 20 2001 878 880
10. J.J. Dajcs, B.A. Thibodeaux, and M.E. Marquart Effectiveness of ciprofloxacin, levofloxacin, or moxifloxacin for treatment of experimental Staphylococcus aureus keratitis Antimicrob Agents Chemother 48 2004 1948 1952
11. A. Dalhoff, and F.J. Schmitz In vitro antibacterial activity and pharmacodynamics of new quinolones Eur J Clin Microbiol Infect Dis 22 2003 203 221
12. G. Foulks Bacterial infections of the conjunctiva and cornea, D.M. Albert F.A. Jakobiec Principles and Practice of Ophthalmology VI, volume 1: 1994 WB Saunders Philadelphia pp 162-71
13. M.H. Goldstein, R.P. Kowalski, Y.J. Gordon, and J. Baum Emerging fluoroquinolone resistance in bacterial keratitis: a 5-year review Ophthalmology 106 1999 1313 1318
14. E.H. Gutierrez Bacterial infections of the eye D. Locatcher-Khorazo B.C. Seegal Microbiology of the Eye 1972 CV Mosby St Louis pp 63-76
15. S.M. Hariprasad, K.J. Blinder, and G.K. Shah Penetration pharmacokinetics of topically administered 0.5% moxifloxacin ophthalmic solution in human aqueous and vitreous Arch Ophthalmol 123 2005 39 43
16. D.G. Hwang Fluoroquinolone resistance in ophthalmology and the potential role for newer ophthalmic fluoroquinolones Surv Ophthalmol 49 Suppl 2 2004 S79 S83
17. R.P. Kowalski, E.G. Romanowski, and F.S. Mah Topical prophylaxis with moxifloxacin prevents endophthalmitis in a rabbit model Am J Ophthalmol 138 2004 33 37
18. J.A. Lohr Treatment of conjunctivitis in infants and children Pediatr Ann 22 1993 359 364
19. NCCLS National Committee for Clinical Laboratory Standards: performance standards for antimicrobial susceptibility testing; twelfth informational supplement 2002 Document M100-S12. Wayne, NCCLS
20. R.J. Olson Challenges in ocular infectious diseases and the evolution of anti-infective therapy Surv Ophthalmol 49 Suppl 2 2004 S53 S54
21. R.J. Olson Reducing the risk of postoperative endophthalmitis Surv Ophthalmol 49 Suppl 2 2004 S55 S61
22. Robertson SM, Curtis MA, Schlech BA,, et al. Ocular pharmacokinetics of moxifloxacin after topical treatment of animals and humans. Surv Ophthalmol 50(Suppl 1):xxx-xxx, 2005
23. B.A. Thibodeaux, J.J. Dajcs, and A.R. Caballero Quantitative comparison of fluoroquinolone therapies of exerimental gram-negative bacterial keratitis Curr Eye Res 28 2004 337 342
24. C.J. Thomson The global epidemiology of resistance of ciprofloxacin and the changing nature of antibiotic resistance: a 10 year perspective J Antimicrob Chemother 43 Suppl A 1999 31 40
25. R. Tipperman Pharmacologic considerations for cataract surgery Curr Opin Ophthalmol 15 2004 51 55
26. P.E. Varaldo Antimicrobial resistance and susceptibility testing: an evergreen topic J Antimicrob Chemother 50 2002 1 4
27. K.R. Wilhelmus, R.L. Abshire, and B.A. Schlech Influence of fluoroquinolone susceptibility on the therapeutic response of fluoroquinolone-treated bacterial keratitis Arch Ophthalmol 121 2003 1229 1233
28. K.R. Wilhelmus, and B.A. Schlech Clinical and epidemiological advantages of culturing bacterial keratitis Cornea 23 2004 38 42